<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00412516</url>
  </required_header>
  <id_info>
    <org_study_id>JEV02</org_study_id>
    <nct_id>NCT00412516</nct_id>
  </id_info>
  <brief_title>Determining Long-Term Safety and Efficacy of Japanese Encephalitis Vaccine When Given With Measles Vaccine</brief_title>
  <official_title>Long-Term Assessment at 24 Months Post-Vaccination of the Non-Inferiority of the Concurrent Administration of Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine and Measles Vaccine to Measles Vaccine Given Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PATH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The previously conducted JEV01 study looked at the immunogenicity and safety of the
      concurrent administration of Japanese Live Attenuated SA 14-14-2 and measles vaccines at the
      one month post vaccination time point. The purpose of the JEV01 study was to help ensure the
      safety of SA 14-14-2 simultaneously administered with measles vaccine, paving the way for its
      use in routine EPI programs. As a follow-on to JEV01, this study will enroll those infants
      who received both vaccines and completed the JEV01 study. This study, however, will provide
      crucial data to help ensure the long-term immunogenicity of the concurrent administration of
      these vaccines and provide valuable information to determine the use of these vaccines in
      routine immunization programs. This study is planned because in the original protocol for
      JEV01, long-term data points were not included. The hypothesis is that children who receive
      JE live attenuated SA 14-14-2 vaccine and measles vaccine at the same time have long-term (24
      and 36 months post vaccination) protection against these diseases at the same level as those
      who receive the vaccines at different intervals.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Japanese encephalitis is the leading cause of viral neurological disease and disability in
      Asia. The severity of sequelae, together with the volume of cases, make JE the most important
      cause of viral encephalitis in the world. Approximately 3 billion people—including 700
      million children—live in Asian areas at risk for JE. JE most commonly infects children
      between the ages of 1 and 15 years, and can also infect adults in areas where the virus is
      newly introduced. More than 50,000 cases are reported annually and cause an estimated 10,000
      to 15,000 deaths. This figure is believed to represent only a small proportion of the disease
      burden that actually exists.

      An effective vaccine has existed since 1941, but has not reached the poorest countries in
      Asia. During the 60 years that the vaccine has been available, JE has infected an estimated
      10.5 million children, resulting in more than 3 million deaths and more than 4 million
      children living with long-term disabilities. Control of this disease has been limited due to
      poor disease surveillance, a limited and unstable vaccine supply, lack of guidance and
      programmatic support for immunization, and limited advocacy.

      A successful vaccine should be safe, efficacious, affordable, administered in a single dose,
      and easily incorporated into the routine Expanded Programmes on Immunization (EPI) programs.

      This trial is designed to determine the potential interference between the measles vaccine
      and the Japanese encephalitis vaccine at 12, 24, and 36 months post-vaccination. As these
      vaccines will be used in routine EPI systems at the same time, similar to how measles and
      yellow fever vaccine (also a Flavivirus) are administered, it is imperative to collect
      long-term data showing that neither vaccine interferes with seroconversion of the other when
      co-administered.This information will help to ensure subject safety and facilitate
      programmatic efficiency, reducing the number of immunization visits for both parents and
      health care workers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measles Seropositivity at 24 and 36 Months</measure>
    <time_frame>24, 36 months post vaccination</time_frame>
    <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measles Seropositivity at 12 Months</measure>
    <time_frame>12 months post vaccination</time_frame>
    <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seropositive Rate for Japanese Encephalitis (JE) Antibody in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</measure>
    <time_frame>12 months, 24 months, and 36 months post vaccination</time_frame>
    <description>&quot;Seropositive&quot; defined as a person with neutralizing antibody against JE virus at a titer ≥ 1:10 in a 50% plaque-reduction neutralizing assay (PRNT-50)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Neutralizing Antibody Titer to Japanese Encephalitis (JE) Virus in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</measure>
    <time_frame>12, 24, 36 months post-JE vaccination</time_frame>
    <description>Neutralizing antibody titer determined using a 50% plaque-reduction neutralizing assay (PRNT-50) for JE virus</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">519</enrollment>
  <condition>Encephalitis, Japanese B</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>JE live attenuated SA 14-14-2 vaccine then measles vaccine after one month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>JE live attenuated SA 14-14-2 vaccine and measles vaccine concurrently</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Measles vaccine then JE live attenuated SA 14-14-2 vaccine after one month</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Live attenuated SA 14-14-2 vaccine</intervention_name>
    <description>Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant was enrolled in the JEV01 study previously conducted at RITM.

          -  Participant completed his/her vaccination schedule for the JEV01 study previously
             conducted at RITM.

          -  Participant's blood test results from JEV01 study indicate that he/she had
             seroconverted to measles vaccination.

          -  Participant's parents or legal guardian are/is willing to provide signed informed
             consent.

        Exclusion Criteria:

          -  Participant was withdrawn from the JEV01 study for any reason.

          -  Receipt of immune globulin or other blood products within 6 months of study (JEV02)
             entry or receipt of injected or oral corticosteroids or other immune modulator therapy
             (except routine vaccines) within 4 weeks of study (JEV02) entry.

          -  Any condition that in the opinion of the investigator, would interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Months</minimum_age>
    <maximum_age>36 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvacion Gatchalian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Tropical Medicine (RITM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute for Tropical Medicine (RITM)</name>
      <address>
        <city>Manila</city>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 14, 2006</study_first_submitted>
  <study_first_submitted_qc>December 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2006</study_first_posted>
  <results_first_submitted>September 30, 2014</results_first_submitted>
  <results_first_submitted_qc>September 30, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2014</results_first_posted>
  <last_update_submitted>October 3, 2014</last_update_submitted>
  <last_update_submitted_qc>October 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 13, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese Encephalitis</keyword>
  <keyword>Japanese B Encephalitis</keyword>
  <keyword>Japanese B Viral Encephalitis</keyword>
  <keyword>Viral Encephalitis, Japanese B</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Measles</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Group 1</title>
          <description>SA 14-14-2 followed by measles vaccine one month later</description>
        </group>
        <group group_id="P2">
          <title>Group 2</title>
          <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
        </group>
        <group group_id="P3">
          <title>Group 3</title>
          <description>Measles vaccine followed by SA 14-14-2 one month later</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="212"/>
                <participants group_id="P3" count="214"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population includes all subjects enrolled in the study</population>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>SA 14-14-2 followed by measles vaccine one month later</description>
        </group>
        <group group_id="B2">
          <title>Group 2</title>
          <description>Measles and SA 14-14-2 given concurrently</description>
        </group>
        <group group_id="B3">
          <title>Group 3</title>
          <description>Measles vaccine followed by SA 14-14-2 one month later</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="212"/>
            <count group_id="B3" value="214"/>
            <count group_id="B4" value="519"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20.6" spread=".4"/>
                    <measurement group_id="B2" value="20.6" spread=".4"/>
                    <measurement group_id="B3" value="20.6" spread=".4"/>
                    <measurement group_id="B4" value="20.6" spread=".4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="117"/>
                    <measurement group_id="B4" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight (kg)</title>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.2" spread="1.3"/>
                    <measurement group_id="B2" value="10.2" spread="1.6"/>
                    <measurement group_id="B3" value="10.2" spread="1.4"/>
                    <measurement group_id="B4" value="10.2" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height (cm)</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.7" spread="3.1"/>
                    <measurement group_id="B2" value="77.8" spread="3.8"/>
                    <measurement group_id="B3" value="78.1" spread="3.5"/>
                    <measurement group_id="B4" value="78.0" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Measles Seropositivity at 24 and 36 Months</title>
        <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
        <time_frame>24, 36 months post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>SA 14-14-2 followed by measles vaccine one month later</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Measles vaccine followed by SA 14-14-2 one month later</description>
          </group>
        </group_list>
        <measure>
          <title>Measles Seropositivity at 24 and 36 Months</title>
          <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
          <units>percentage of participants seropositive</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="213"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>24 months post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.92" lower_limit="94.15" upper_limit="99.97"/>
                    <measurement group_id="O2" value="95.75" lower_limit="92.09" upper_limit="98.04"/>
                    <measurement group_id="O3" value="94.37" lower_limit="90.37" upper_limit="97.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months post vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.62" lower_limit="87.90" upper_limit="98.23"/>
                    <measurement group_id="O2" value="91.39" lower_limit="86.73" upper_limit="94.82"/>
                    <measurement group_id="O3" value="91.04" lower_limit="86.36" upper_limit="94.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measles Seropositivity at 12 Months</title>
        <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
        <time_frame>12 months post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>SA 14-14-2 followed by measles vaccine one month later</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Measles vaccine followed by SA 14-14-2 one month later</description>
          </group>
        </group_list>
        <measure>
          <title>Measles Seropositivity at 12 Months</title>
          <description>Seropositivity defined as an anti-MV IgG concentration of 120 mIU/mL determined with the Siemens ELISA</description>
          <units>percentage of subjects seropositive</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="205"/>
                <count group_id="O3" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.64" lower_limit="78.96" upper_limit="93.67"/>
                    <measurement group_id="O2" value="87.32" lower_limit="81.97" upper_limit="91.55"/>
                    <measurement group_id="O3" value="87.2" lower_limit="81.93" upper_limit="91.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seropositive Rate for Japanese Encephalitis (JE) Antibody in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</title>
        <description>“Seropositive” defined as a person with neutralizing antibody against JE virus at a titer ≥ 1:10 in a 50% plaque-reduction neutralizing assay (PRNT-50)</description>
        <time_frame>12 months, 24 months, and 36 months post vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>SA 14-14-2 followed by measles vaccine one month later</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Measles vaccine followed by SA 14-14-2 one month later</description>
          </group>
        </group_list>
        <measure>
          <title>Seropositive Rate for Japanese Encephalitis (JE) Antibody in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</title>
          <description>“Seropositive” defined as a person with neutralizing antibody against JE virus at a titer ≥ 1:10 in a 50% plaque-reduction neutralizing assay (PRNT-50)</description>
          <units>percentage of subjects seropositive</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.4" lower_limit="81.9" upper_limit="95.8"/>
                    <measurement group_id="O2" value="83.5" lower_limit="77.6" upper_limit="88.4"/>
                    <measurement group_id="O3" value="86.1" lower_limit="80.6" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.1" lower_limit="71.5" upper_limit="88.6"/>
                    <measurement group_id="O2" value="83.8" lower_limit="77.8" upper_limit="88.6"/>
                    <measurement group_id="O3" value="80.7" lower_limit="74.6" upper_limit="85.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.3" lower_limit="69.3" upper_limit="87.2"/>
                    <measurement group_id="O2" value="82.7" lower_limit="76.7" upper_limit="87.6"/>
                    <measurement group_id="O3" value="81.9" lower_limit="75.8" upper_limit="87.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Neutralizing Antibody Titer to Japanese Encephalitis (JE) Virus in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</title>
        <description>Neutralizing antibody titer determined using a 50% plaque-reduction neutralizing assay (PRNT-50) for JE virus</description>
        <time_frame>12, 24, 36 months post-JE vaccination</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 1</title>
            <description>SA 14-14-2 followed by measles vaccine one month later</description>
          </group>
          <group group_id="O2">
            <title>Group 2</title>
            <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
          </group>
          <group group_id="O3">
            <title>Group 3</title>
            <description>Measles vaccine followed by SA 14-14-2 one month later</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Neutralizing Antibody Titer to Japanese Encephalitis (JE) Virus in Infants in the Philippines Who Received Measles Vaccine (MV) Before, With, or After SA 14-14-2 JE Vaccination by Month After JE Vaccination.</title>
          <description>Neutralizing antibody titer determined using a 50% plaque-reduction neutralizing assay (PRNT-50) for JE virus</description>
          <units>GMT</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="212"/>
                <count group_id="O3" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>12 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="108" lower_limit="70" upper_limit="167"/>
                    <measurement group_id="O2" value="83" lower_limit="61" upper_limit="108"/>
                    <measurement group_id="O3" value="77" lower_limit="60" upper_limit="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67" lower_limit="46" upper_limit="99"/>
                    <measurement group_id="O2" value="64" lower_limit="50" upper_limit="80"/>
                    <measurement group_id="O3" value="70" lower_limit="54" upper_limit="92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months post-JE vaccination</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" lower_limit="37" upper_limit="71"/>
                    <measurement group_id="O2" value="47" lower_limit="38" upper_limit="58"/>
                    <measurement group_id="O3" value="58" lower_limit="45" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Three years post vaccination</time_frame>
      <desc>Since no investigational products were administered to subjects during the course of this study, subjects were not actively monitored to detect adverse events (AEs). However, passive surveillance was maintained to note reports of events meeting the definition of a serious AE (SAE).</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1</title>
          <description>SA 14-14-2 followed by measles vaccine one month later</description>
        </group>
        <group group_id="E2">
          <title>Group 2</title>
          <description>Measles and SA 14-14-2 given concurrently
Live attenuated SA 14-14-2 vaccine: Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)</description>
        </group>
        <group group_id="E3">
          <title>Group 3</title>
          <description>Measles vaccine followed by SA 14-14-2 one month later</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental delay</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Bronchopneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Cholera</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Dengue Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="214"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="212"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="214"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All results communication must be reviewed and approved by the sponsor. The sponsor has 60 days to review results communications and provide comments.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony A Marfin, Director Japanese Encephalitis Vaccine Introduction and Sustainability Project</name_or_title>
      <organization>PATH</organization>
      <phone>2062853500</phone>
      <email>aamarfin@path.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

